INO
Price
$1.48Alerts
Change
+$0.03 (+2.07%)
Updated
Nov 11 closing price
Capitalization
125.63M
111 days until earnings call
Intraday BUY SELL Signals
ORMP
Price
$4.13Alerts
Change
+$0.16 (+4.03%)
Updated
Nov 11 closing price
Capitalization
160.57M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INO vs ORMP

INO vs ORMP Comparison Chart in %
View a ticker or compare two or three
VS
INO vs. ORMP commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a Hold and ORMP is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for INO with price predictions
Nov 10, 2026

INO's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for INO moved out of overbought territory on November 03, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 18 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 52 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.

INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.498). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for ORMP with price predictions
Nov 10, 2026

ORMP's RSI Indicator climbs out of oversold territory

The RSI Oscillator for ORMP moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 24 of the 29 cases the stock moved higher. This puts the odds of a move higher at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ORMP just turned positive on November 10, 2026. Looking at past instances where ORMP's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 70 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

The 10-day moving average for ORMP crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ORMP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.498). P/E Ratio (0.910) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.259) settles around the average of (130.981) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
INO vs ORMP: Fundamental Ratings
INO
ORMP
OUTLOOK RATING
1..100
919
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10015
PRICE GROWTH RATING
1..100
3548
P/E GROWTH RATING
1..100
6094
SEASONALITY SCORE
1..100
3850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (67) in the Pharmaceuticals Other industry is in the same range as INO (90) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's SMR Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew significantly faster than INO’s over the last 12 months.

INO's Price Growth Rating (35) in the Medical Specialties industry is in the same range as ORMP (48) in the Pharmaceuticals Other industry. This means that INO’s stock grew similarly to ORMP’s over the last 12 months.

INO's P/E Growth Rating (60) in the Medical Specialties industry is somewhat better than the same rating for ORMP (94) in the Pharmaceuticals Other industry. This means that INO’s stock grew somewhat faster than ORMP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOORMP
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (INO: $1.45 vs. ORMP: $3.97)
Brand notoriety: INO: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 102% vs. ORMP: 60%
Market capitalization -- INO: $125.63M vs. ORMP: $160.57M
INO [@Biotechnology] is valued at $125.63M. ORMP’s [@Biotechnology] market capitalization is $160.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green while ORMP’s FA Score has 1 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 1 green, 4 red.
According to our system of comparison, ORMP is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 5 bearish.
  • ORMP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both INO and ORMP are a good buy in the short-term.

Price Growth

INO (@Biotechnology) experienced а -12.65% price change this week, while ORMP (@Biotechnology) price change was -0.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

INO is expected to report earnings on Mar 02, 2027.

ORMP is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-3.97%
AXON - INO
53%
Loosely correlated
-0.21%
ARRY - INO
52%
Loosely correlated
-8.86%
LPCN - INO
41%
Loosely correlated
-7.56%
AMRN - INO
39%
Loosely correlated
+0.09%
PCSA - INO
38%
Loosely correlated
-4.10%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TOLL40.310.06
+0.14%
Tema Durable Quality ETF (TOLL)
SBB23.15N/A
N/A
ProShares Short SmallCap600 (SBB)
EVIM52.24-0.09
-0.18%
Eaton Vance Intermediate Municipal Income ETF (EVIM)
EPP55.99-0.38
-0.67%
iShares MSCI Pacific ex-Japan ETF (EPP)
IZRL26.10-0.43
-1.61%
ARK Israel Innovative Technology ETF (IZRL)